Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
| ▸ | PNP | P00491 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 1/20 | 0.51 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10819892 | 1.00 | TGM2 (0.59) | TGM2P2RY2P2RY4POLBFUT5 | |
| SCHEMBL13522449 | 1.00 | TGM2 (0.59) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL10819844 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL13522450 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL14946248 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL23319265 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL14929056 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL21006183 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL21007234 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 | |
| Inx-09114 SCHEMBL720114 | 0.99 | P2RY2 (0.60) | TGM2P2RY2P2RY4POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307434-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2476690-A1 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2307434-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | CRETTON-SCOTT ERIKA | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003217-A1 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | HAVCR2, PYGL, GOT1 | TGM2 397/4885P2RY2 2250/4885P2RY4 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.